Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $1.06, $1.01 better than the analyst estimate of $0.05. Revenue for the quarter came in at $231.1 million versus the consensus estimate of $203.67 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.